Top in allergy/asthma: OFCs for children; inaccurate penicillin allergy labels delabeled
Click Here to Manage Email Alerts
An expert at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting addressed the fear surrounding oral food challenges in infants and toddlers and discussed why they should not be deferred.
Most commonly, oral food challenges are conducted to confirm or rule out food allergy diagnoses and to follow up with allergy treatment if needed.
“Don’t be afraid of infant and toddler challenges, and don’t underuse them,” Aikaterini (Katherine) Anagnostou, MD, MSc, PhD, FACAAI, professor of pediatric allergy at Texas Children’s Hospital and Baylor College of Medicine, said during her presentation.
“We have new prevention guidelines; we know we can safely introduce foods to all infants,” she added.
Anagnostou recommends that physicians have conversations about preparation with families prior to oral food challenges and provide clear instructions on how to proceed if an allergic reaction occurs.
It was the top story in allergy/asthma last week.
In another top story, a team of generalists, specialists, residents and medical students successfully delabeled 14 of 121 patients with a penicillin allergy label in a primary care office. Additionally, 13 out of 31 patients referred to an allergist were delabeled.
Read these and more top stories in allergy/asthma below:
Physicians encouraged to conduct oral food challenges for infants, toddlers
Physicians should not hesitate to conduct oral food challenges for infants and toddlers, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Read more.
Inaccurate pediatric penicillin allergy labels successfully delabeled
Delabeling inappropriate penicillin allergy labels in outpatient pediatric patients is feasible, according to an abstract presented at the American Academy of Pediatrics National Conference & Exhibition. Read more.
Racially diverse patients exhibit less vaccine hesitancy
Vaccine hesitancy occurred less frequently in racially diverse vs. white patients, although this hesitancy was not significantly impacted by age, sex or language, according to a poster presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Read more.
Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial
Healio spoke with Jessica Grossman, MD, CEO of IgGenix, about IGNX001, a monoclonal antibody-based therapeutic for peanut allergy, and what it means for patients. Read more.
FDA accepts new drug application for donidalorsen
The FDA accepted a new drug application for review of donidalorsen, a prophylactic RNA-targeting drug used to prevent hereditary angioedema attacks in patients aged 12 years and older, according to a press release from Ionis. Read more.